Navigation Links
New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
Date:3/31/2008

CHICAGO, March 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that preclinical research presented at the American College of Cardiology 57th Annual Scientific Session in Chicago showed that ranolazine increased glucose-stimulated insulin secretion (GSIS) in pancreatic islets isolated from animals and humans.

The Company believes that the increase in GSIS seen with ranolazine may contribute to the statistically significant reductions in hemoglobin A1c (HbA1c) levels observed with Ranexa in cardiovascular patients with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and MERLIN-TIMI 36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials. In CARISA, Ranexa reduced HbA1c levels by an average of up to 0.7 percentage points. In MERLIN-TIMI 36, Ranexa lowered HbA1c versus placebo by an average of 0.43 percentage points at four months in patients with a mean baseline HbA1c level of 7.5%.

The preclinical results presented today showed that ranolazine increased GSIS in a dose-dependent manner in isolated islets. Acute administration of ranolazine to animals also significantly increased GSIS in the presence of a glucose load (p<0.05). Peak increases in insulin levels from ranolazine were similar to those seen with glibenclamide, a sulfonylurea used as a positive control. Unlike glibenclamide, in the absence of glucose ranolazine did not have any effect on insulin secretion.

"These data provide important additional information on the potential underlying mechanism which may be responsible for significant HbA1c reductions without associated hypoglycemia in both the CARISA and MERLIN-TIMI 36 studies," said Luiz Belardinelli, M.D., senior vice president of pharmaco
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 GenomeDx Biosciences today ... the American Society for Radiation Oncology (ASTRO) Annual ... Cancer Classifier, a genomic test capable of predicting ... and improve patient outcomes for prostate cancer patients ... a recently published study that demonstrates how Decipher ...
(Date:9/15/2014)...  Alere Inc. (NYSE: ALR ) (the ... toxicology, cardiology and diabetes products and services, today confirmed ... CEO Ron Zwanziger , filed a Schedule 13D ... a letter to Gregg J. Powers , Chairman ... in an effort to secure financing to make a ...
(Date:9/15/2014)... Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. ... pharmaceutical company with a focus on Omega-3 therapies ... that the Board of Directors approved the granting ... advisor at the close of business on Friday, September ... 1,000,000 common shares of the Company were granted ...
Breaking Medicine Technology:Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Alere Responds To Letter From Former Executives 2Pivotal Therapeutics Grants Incentive Stock Options 2
... May 9, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... abstracts at the 2011 Digestive Disease Week (DDW) conference ... of DIFICID™ (fidaxomicin), an investigational product for the treatment ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The first analysis ...
... Australia and BEIJING, May 9, 2011 Saladax Biomedical, ... diagnostic assays to achieve the promise of personalized medicine ... of its Pacific Rim commercialization team to expand its ... Saladax,s Pacific Rim commercialization team include: ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China 2
(Date:9/15/2014)... MONDAY, Sept. 15, 2014 (HealthDay News) -- U.S. heart ... an electrocardiogram (ECG) when evaluating young people for underlying ... The American Heart Association and the American College ... more detailed personal and family medical history along with ... genetic or congenital (existing from birth) risks for sudden ...
(Date:9/15/2014)... (PRWEB) September 16, 2014 “Canada ... market data on the Canada Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Female Sterilization Devices (Transcervical Sterilization Devices ... Rings) , Endometrial Ablation Devices (Thermal ...
(Date:9/15/2014)... Maureen Salamon HealthDay ... -- Pediatricians prescribe antibiotics about twice as often as ... infections, a new study indicates. More than 11 ... teens may be unnecessary, according to researchers from University ... use not only fails to eradicate children,s viral illnesses, ...
(Date:9/15/2014)... 15, 2014 As Colorado's historic ... its first full year, there are a variety ... in the evolution of its marketing and branding. ... taken by Denver's Kindman, one of the state's ... , Kindman has pioneered the first-ever branded and ...
(Date:9/15/2014)... Physicians and clinicians from around ... at the Lowes Coronado Bay Resort for the ... . This CME accredited medical conference ... healthcare professionals—about the nutritional science that overwhelmingly supports ... its proven ability to prevent, suspend and, often, ...
Breaking Medicine News(10 mins):Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 2Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 3Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 4Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:San Diego Plays Host This Week to International Plant-based Nutrition Healthcare Conference Featuring Drs. Ornish, Esselstyn, Campbell and Other Leading Experts 2Health News:San Diego Plays Host This Week to International Plant-based Nutrition Healthcare Conference Featuring Drs. Ornish, Esselstyn, Campbell and Other Leading Experts 3
... the Netherlands have identified a chemical agent that may ... syndrome (BOS), or popcorn workers lung, a severe occupational ... an American plant that makes microwaveable popcorn. ... at a chemical plant that produced diacetyl (a key ...
... the way toward screening people at risk for lung ... researchers from the University of Colorado say. , The ... prevention, said researcher Wilbur A. Franklin, M.D., Professor of ... Our goal would be to develop screening techniques for ...
... the Board, SAN DIEGO, Aug. 30 ResMed ... of directors has unanimously approved a,succession plan for executive ... Gallahue will be promoted to Chief Executive Officer and,will ... succeed Dr. Peter,C. Farrell, 65. As of January 1, ...
... The United States,Government, through the U.S. Agency for ... million in equipment and technical,assistance to the Government ... country. This announcement follows the provision of an ... the Hellenic Red Cross for emergency,fire fighting equipment ...
... grants 1500 Caregivers, members of SEIU UHW-West and 121RN, ... and classification at hospital, BURBANK, Calif., Aug. 30 ... members of SEIU United Healthcare Workers -,West (UHW) and ... Providence St. Joseph Medical Center. The contract, which expires,Sept. ...
... Four-Star,General Barry McCaffrey (ret), former White House National Drug ... International,Affairs and a widely cited terrorism and drug policy ... Chair of a State Capitol rally for,recovery and treatment ... at,11:30. Also speaking will be California HHS Secretary ...
Cached Medicine News:Health News:Chemical culprit in 'popcorn worker's lung' identified 2Health News:New technique detects specific chromosomal damage, may indicate lung cancer risk 2Health News:ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008. 2Health News:Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract 2Health News:4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote 'Recovery Happens!' Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento 2
... EX accelerators are true ... Varian multileaf collimation and ... which enable you to ... computer-driven IMRT treatments, as ...
The Clinac 2100 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
The Clinac 6EX accelerator is a cost-effective choice. Configured for the latest treatment techniques, the Clinac 6EX has the tightest mechanical and dosimetric specifications for any single-energy m...
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
Medicine Products: